Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cerevel Therapeutics Holdings (CERE – Research Report), Genmab (GMAB – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report).
Cerevel Therapeutics Holdings (CERE)
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Cerevel Therapeutics Holdings on November 1 and set a price target of $25.00. The company’s shares closed last Friday at $26.36.
According to TipRanks.com, Suvannavejh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cerevel Therapeutics Holdings with a $31.50 average price target, which is a 25.7% upside from current levels. In a report issued on November 1, Wells Fargo also maintained a Hold rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Genmab (GMAB)
Leerink Partners analyst Jonathan Chang maintained a Hold rating on Genmab on November 2. The company’s shares closed last Friday at $29.09, close to its 52-week low of $27.74.
According to TipRanks.com, Chang has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Genmab is a Moderate Buy with an average price target of $46.00.
BioMarin Pharmaceutical (BMRN)
Robert W. Baird analyst Joel Beatty maintained a Buy rating on BioMarin Pharmaceutical on November 1 and set a price target of $127.00. The company’s shares closed last Friday at $79.59, close to its 52-week low of $76.02.
According to TipRanks.com, Beatty is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $110.29 average price target, a 37.6% upside from current levels. In a report issued on October 25, Piper Sandler also maintained a Buy rating on the stock with a $125.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CERE:
- Cerevel Therapeutics reports Q3 EPS (61c), consensus (63c)
- Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
- Insider Trading: Cerevel (NASDAQ:CERE) Gains on Director’s Massive Buy
- Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
- Cerevel Therapeutics 19.73M share Spot Secondary priced at $22.81
